Compare OVID & UAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVID | UAC |
|---|---|---|
| Founded | 2014 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 140.2M |
| IPO Year | 2017 | 2026 |
| Metric | OVID | UAC |
|---|---|---|
| Price | $2.51 | $9.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 28.7K |
| Earning Date | 03-18-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | $1,077.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $0.24 | $9.51 |
| 52 Week High | $2.72 | $9.95 |
| Indicator | OVID | UAC |
|---|---|---|
| Relative Strength Index (RSI) | 76.72 | 51.99 |
| Support Level | $1.31 | $9.83 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 82.11 | 100.00 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.